

## 培美曲塞治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效观察

刘明月<sup>1</sup>, 侯桂琴<sup>2</sup>, 高天慧<sup>1</sup>, 崔瑶<sup>1</sup>, 李晓燕<sup>1</sup>, 周云<sup>1</sup>

1.450003郑州, 河南省人民医院肿瘤科; 2.郑州大学药学院

## Efficacy of Pemetrexed Chemotherapy in Advanced Non-small Cell Lung Cancer with EGFR-TKI Resistance

Liu Mingyue<sup>1</sup>, Hou Guiqin<sup>2</sup>, Gao Tianhui<sup>1</sup>, Cui Yao<sup>1</sup>, Li Xiaoyan<sup>1</sup>, Zhou Yun<sup>1</sup>

1.Department of Oncology, People's Hospital of He'nan Province, Zhengzhou 450003, China; 2.School of Pharmaceutical Sciences, Zhengzhou University

- 摘要
- 参考文献
- 相关文章

全文: PDF (997 KB) HTML (1 KB) 输出: BibTeX | EndNote (RIS) 背景资料

### 摘要

### 目的

观察培美曲塞治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌(非鳞癌)的疗效。方法14例患者入组, 2例既往未接受化疗患者采用培美曲塞联合顺铂方案, 培美曲塞 500 mg/m<sup>2</sup>, 静脉滴注, d1; DDP 25 mg/m<sup>2</sup>, 静脉滴注d1~d3。12例既往曾接受含铂两药联合方案化疗患者(不含培美曲塞), 采用培美曲塞单药化疗500 mg/m<sup>2</sup>, d1; 21天为一周期。所有患者均接受2周期以上治疗。结果14例患者均接受2周期以上治疗, 可评价疗效。治疗有效率35.7% (5/14), 疾病控制率71.4% (10/14), 中位疾病进展时间(PFS)为6.3月, 中位生存期为12.5月。结论培美曲塞治疗EGFR-TKI治疗失败后晚期非小细胞肺癌取得一定疗效, 不良反应可以耐受, 值得临床进一步研究。

关键词: 培美曲塞 非小细胞肺癌 化学治疗

### Abstract:

### Objective

To observe the efficacy and toxicity of Pemetrexed chemotherapy in advanced non-small cell lung cancer, failed to EGFR-TKI treatment. Methods Fourteen patients were enrolled. Two patients without chemotherapy history were treated by pemetrexed combined with cisplatin; pemetrexed 500 mg/m<sup>2</sup>, intravenously, d1; DDP 25 mg/m<sup>2</sup>, d1~d3, intravenously. Twelve cases received platinum-based chemotherapy were treated with pemetrexed 500 mg/m<sup>2</sup> alone, 21 days for one cycle. All patients received at least 2 cycles of treatment. Results All 14 patients had been evaluated. Overall response rate was 35.7% (5/14), and disease control rate was 71.4% (10/14). Median progression-free survival (PFS) and overall survival (OS) were 6.3 months and 12.5 months, respectively. Conclusion Pemetrexed might improve clinically outcomes with well tolerance for advanced non-small cell lung cancer resisted to EGFR-TKI.

Key words: Pemetrexed Non-small cell lung cancer Chemotherapy

收稿日期: 2012-02-29;

通讯作者: 周云, E-mail: zhl1336@163.com E-mail: zhl1336@163.com

作者简介: 刘明月(1976-), 女, 硕士, 主治医师, 主要从事恶性肿瘤的综合治疗

### 引用本文:

刘明月, 侯桂琴, 高天慧等. 培美曲塞治疗EGFR-TKI获得性耐药的晚期非小细胞肺癌疗效观察[J]. 肿瘤防治研究, 2012, 39(6): 713-715.

### 服务

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ E-mail Alert
- ▶ RSS

### 作者相关文章

- ▶ 刘明月
- ▶ 侯桂琴
- ▶ 高天慧
- ▶ 崔瑶
- ▶ 李晓燕
- ▶ 周云

[1]

[1] S Song ZB,Lu S,Yu YF,et al.Sequential erlotinib in combination with chemotherapy in the treatment

[2]

of advanced non-small cell lung cancer [J] .Lin Chuang Zhong Liu Xue Za Zhi,2010,15(1):48-51. [宋正

[3]

波, 陆舜, 虞永峰, 等.化疗期间序贯应用厄洛替尼治疗晚期非小细胞肺癌的临床观察 [J] .临床肿瘤学杂志,

[4]

201010, 15(1): 48-51.]

[5]

[2] ZZhang B,Zhang X,Gao YJ,et al.Clinical observation of pemetrexed monotherapy or combination

[6]

regimen as second-line treatment for advanced non-small cell lung cancer [J] .Lin Chuang Zhong Liu

[7]

Xue Za Zhi,2011,16(10):41-6. [张斌, 张霞, 高亚杰, 等, 培美曲塞单药与联合用药治疗复发晚期非小细胞肺

[8]

癌的临床观察 [J] .临床肿瘤学杂志, 2011, 16(10):41-6.]

[9]

[3] WWu JY,Shih JY,Yang CH,et al.Second-line treatments after first-line gefitinib therapy in

[10]

advanced nonsmall cell lung cancer [J] .Int J Cancer,2010,126(1):247-55.

[11]

[4] KKuo CH,Lin SM,Lee KY,et al.Subsequent chemotherapy improves survival outcome in advanced non-

[12]

small cell lung cancer with acquired tyrosine kinase inhibitor resistance [J] .Clin Lung

[13]

Cancer,2010,11(1):51-6.

[14]

[5] CChang MH,Ahn JS,Lee J,et al.The efficacy of pemetrexed as a third or fourth line therapy and

[15]

the significance of thymidylate synthase expression in patients with advanced non small cell lung

[16]

cancer [J] .Lung Cancer,2010,69(3):323-9.

[17]

[6] YYang JL,Zhang XC,Yuan XM,et al.Clinical observation of palliative chemotherapy for 16 patients

[18]

with advanced non-small cell lung cancer failed in treatment of EGFR-TKI [J] .Shi Yong Zhong Liu Za

[19]

Zhi,2011,26(1):55-8. [杨军礼,张秀春,袁霞妹,等.姑息化疗EGFR-TKI治疗失败后晚期非小细胞肺癌临床疗效观察

[20]

[J] .实用肿瘤杂志,2011,26(1):55-8.]

[21]

[7] FFan Y,Huang ZY,Yu HF,et al.Efficacy of salvage chemotherapy in the advanced non-small cell lung

[22]

[23]

Zhi,2010,32(11):859-63. [范云,黄志煜,余海峰,等.挽救性化疗治疗化疗及表皮生长因子受体酪氨酸激酶抑制剂

[24]

治疗失败的晚期非小细胞肺癌的疗效和安全性 [J]. 中华肿瘤杂志,2010,32(11):859-63.]

[25]

[8] C Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care

[26]

versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-

[27]

blind, phase 3 study [J]. Lancet, 2009, 374(9699): 1432-40.

- [1] 张鲁昌,阿迪力·萨来,张国庆,韩峰,房新志,张银华. IL-17、MMP-9在汉族和维吾尔族非小细胞肺癌患者中的表达及临床意义[J]. 肿瘤防治研究, 2012, 39(7): 798-801.
- [2] 牛飞玉, 吴一龙. 非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂的耐药机制及对策[J]. 肿瘤防治研究, 2012, 39(7): 865-868.
- [3] 别志欣综述, 李琳审校. MicroRNA在非小细胞肺癌中的研究进展[J]. 肿瘤防治研究, 2012, 39(6): 739-743.
- [4] 王娟, 纪钧, 蔡忠仁, 陈大可, 黎辰, 陈勇. 金米益肺汤对非小细胞肺癌患者血清VEGF表达的影响[J]. 肿瘤防治研究, 2012, 39(5): 567-569.
- [5] 沈文斌, 祝淑钗, 高红梅, 李娟, 苏景伟, 刘志坤, 李幼梅, 万钧. 三维适形大分割放射治疗局部中晚期非小细胞肺癌的不良反应与长期生存分析[J]. 肿瘤防治研究, 2012, 39(5): 577-581.
- [6] 王霞, 成健, 王亚帝, 哈敏文, 王艳. TS基因3' -UTR多态性与晚期肺腺癌患者对培美曲塞敏感度的关系[J]. 肿瘤防治研究, 2012, 39(3): 272-277.
- [7] 姚元虎, 章龙珍, 吴阳, 辛勇, 唐天友, 王建设, 张鑫君, 覃朝晖. 累及野调强放疗联合同步化疗治疗局部晚期非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 2012, 39(3): 321-323.
- [8] 杨留中, 崔艳慧, 寇卫政, 寇小格, 苗战会, 牛红蕊. 多西紫杉醇联合沙立度胺片二线治疗晚期非小细胞肺癌的临床观察[J]. 肿瘤防治研究, 2012, 39(3): 324-328.
- [9] 王永涛, 孙小亮, 崔玉忠, 赵如森. microRNA-130a在非小细胞肺癌中的表达及其意义[J]. 肿瘤防治研究, 2012, 39(3): 278-280.
- [10] 王小莉, 龚兴牡. Trx-1和COX-2在非小细胞肺癌中的表达及意义[J]. 肿瘤防治研究, 2012, 39(2): 166-168.
- [11] 杭晓声, 史央, 李丽, 项方, 时宏珍. 树突状细胞免疫治疗晚期非小细胞肺癌的临床观察[J]. 肿瘤防治研究, 2012, 39(2): 205-209.
- [12] 张华, 冯卫能, 邓燕明, 冼海兵. 培美曲塞联合顺铂一线治疗晚期非鳞状非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 2012, 39(1): 88-90.
- [13] 王力军, 冯济龙. 三维适形放疗联合小剂量顺铂治疗老年非小细胞肺癌的疗效观察[J]. 肿瘤防治研究, 2012, 39(1): 85-87.
- [14] 童皖宁, 张军, 卓安山, 曹玉书. 伽玛刀联合培美曲塞/卡铂同步治疗局部晚期非小细胞肺癌的临床观察[J]. 肿瘤防治研究, 2012, 39(1): 81-84.
- [15] 刘先领, 曾惠爱, 马芳, 杨农. 吉西他滨联合顺铂治疗复发转移性乳腺癌的疗效观察[J]. 肿瘤防治研究, 2011, 38(9): 1055-1057.